ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

摘要:

Researchers analysing the results of the Val-HeFT*trial found that patients with heart failure (HF) treated with the angiotensin II receptor antagonist valsartan experienced enhanced quality of life (QOL), compared with patients who received placebo. In a poster presentation at the 51st annual scientific sessions of the American College of Cardiology [Atlanta, Georgia, US; March 2002], physicians reported that the 1506 patients receiving placebo showed worsening of scores on a standard QOL instrument, while the 1504 patients who received valsartan ['Diovan'; Novartis Pharmaceutical Corporation] had QOL scores that essentially remained constant, relative to their baseline assessment, during the 30 months following randomisation.

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

摘要:

Although the anticancer properties of an enormous number of compounds are being investigated in preclinical studies, few of these will enter clinical development, and even fewer will eventually reach the market. A strong focus on compounds at the preclinical stage of development is expected at the Annual Meeting of the American Association of Cancer Research (AACR) and this year's conference [San Francisco, US; April 2002] was no exception. However, this year's meeting also featured results from phase I and II studies of promising new agents in the treatment of a wide range of cancers.

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2002

数据来源: ADIS